Item 5. Market for Registrant’s Common Equity
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Our common stock is listed and traded under the ticker symbol “PCRX” on the Nasdaq Global Select Market. As of February 27, 2023, we had 11 holders of record of our common stock. The number of record holders is based on the actual number of holders registered on the books of our transfer agent and does not reflect the substantially greater amount of holders of shares in “street name”, whose shares are held of record by banks, brokers and other financial institutions.
Performance Graph
The following graph shows the value of an investment of $100.00 made on December 29, 2017—the last trading day of 2017—in each of Pacira BioSciences, Inc. (PCRX), the Nasdaq Composite Index (^IXIC), the Nasdaq Biotechnology Index (^NBI) and the S&P Pharmaceuticals Select Index (^SPSIPH). The three indices included are for comparative purposes only and do not necessarily reflect management’s opinion that such indices are an appropriate measure of the relative performance of our common stock. All results assume the reinvestment of dividends, if any, and are calculated as of December 31 st of each year. The historical stock price performance of our common stock and the indices shown in this performance graph is not necessarily indicative of future stock price performance.
Comparison of Five-Year Cumulative Total Returns
Among Pacira BioSciences, Inc., the Nasdaq Composite Index,
the Nasdaq Biotechnology Index and the S&P Pharmaceuticals Select Index
Cumulative Total Return as of December 31,
2017 2018 2019 2020 2021 2022
Pacira BioSciences, Inc. (PCRX) $ 100.00 $ 94.24 $ 99.23 $ 131.08 $ 131.81 $ 84.58
Nasdaq Composite Index (^IXIC) $ 100.00 $ 96.12 $ 129.97 $ 186.69 $ 226.63 $ 151.61
Nasdaq Biotechnology Index (^NBI) $ 100.00 $ 90.68 $ 112.81 $ 141.78 $ 140.88 $ 125.52
S&P Pharmaceuticals Select Index (^SPSIPH) $ 100.00 $ 84.29 $ 105.16 $ 119.45 $ 106.02 $ 94.15
Dividend Policy
We have never declared or paid any dividends on our common stock. We currently intend to retain any future earnings to finance the future development and expansion of our business, and as such we do not expect to pay any cash dividends on our common stock in the foreseeable future. The payment of future dividends, if any, will be at the discretion of our board of directors and will depend on our financial condition, results of operations, capital requirements, restrictions contained in the agreements governing our indebtedness, provisions of applicable law and any other factors our board of directors deems relevant.
Pacira BioSciences, Inc. | 2022 Form 10-K | Page 69
Tab le of Contents
Item 6. Reserved
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.